[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573759":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":41,"locations":32,"responsibleParty":47,"collaborators":32,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":32,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":32,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":32,"overallStatus":72,"whyStopped":32,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":32},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"GroupⅠ(n=25) (Control group)","PLACEBO_COMPARATOR","This group will include twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors who will receive placebo tablets once daily for 14 days pre-operative.",[13],"Drug: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"GroupII (n=25) (Dapagliflozin group)","EXPERIMENTAL","This group will include twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors who will receive Dapagliflozin 10 mg once daily for 14 days pre-operative.",[19],"Drug: Dapagliflozin placebo",{"label":21,"type":22,"description":23,"interventionNames":24},"Group III (n=25) (Dexamethasone group)This group will include twenty-five non-diabetic glioma patien","ACTIVE_COMPARATOR","This group will include twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors who will receive Dexamethasone 8 mg tablets once daily for 14 days pre-operative.",[25],"Drug: DexamethasoneGroup III (n=25) (Dexamethasone group)",[27,33,37],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Dapagliflozin placebo","Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dapagliflozin 10 mg once daily for 14 days pre-operative",[15],null,{"type":28,"name":34,"description":35,"armGroupLabels":36,"otherNames":32},"Placebo","Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive placebo tablets once daily for 14 days pre-operative.",[9],{"type":28,"name":38,"description":39,"armGroupLabels":40,"otherNames":32},"DexamethasoneGroup III (n=25) (Dexamethasone group)","Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dexamethasone 8 mg tablets once daily for 14 days pre-operative.",[21],[42],{"name":43,"role":44,"phone":45,"phoneExt":32,"email":46},"Maha Khalifa, master","CONTACT","0201092848424","maha142282@pharm.tanta.edu.eg",{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","Maha Khalifa","PhD Candidate","100573759","phase-3-dapagliflozin-versus-dexamethasone-role-in-pre-operative-management-of-non--diabetic-brain-tumor-patients-100573759",false,"NCT06750458","Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients","Comparative Study Between Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients","Inclusion Criteria:\n\n* Males \\& females.\n* Age: between 18 and 75 years old.\n* Pre-operative non-diabetic glioma patients on levetiracetam. • Diagnosis will be confirmed by:\n\n  * The initial clinical examination.\n  * Magnetic resonance imaging of the brain (MRI) with contrast.\n\nExclusion Criteria:\n\n* Age: \\> 75 years old, and \\\u003C18 years old.\n* Breast feeding female. • Pregnant female.\n* eGFR\\\u003C 30 mL\u002Fminute\u002F1.73 m2.\n* Patients with diabetes mellitus.\n* Patients with diabetic ketoacidosis.\n* Patients with urinary tract infection.\n* Dehydrated patients till normalized.\n* Lower limb amputation patients.\n* SGLT2 inhibitors hypersensitivity.\n* Severe hepatic patients (child-plug score class-c).","ALL","18 Years","75 Years",{"count":62,"type":63},75,"ESTIMATED","INTERVENTIONAL",[66],"PHASE3","The aim of the study is to compare between the role of dapagliflozin versus dexamethasone in pre-operative management of non-diabetic glioma patients on levetiracetam as anti-seizure drug.",[69,70,71],"Glioma","Dapagliflozin (Forxiga)","Dexamethasone","NOT_YET_RECRUITING","2025-04-20",{"date":75,"type":76},"2025-04-22","ACTUAL",{"date":78,"type":63},"2025-08-20",{"date":80,"type":63},"2026-12-20",{"name":5,"class":6}]